bpc 157 peptide safety human studies Multifunctionality and Possible Medical Application of the Peptide—Literature and Patent Review The Hidden Risks of BPC‑157:

Hypertension NSAIDs, including ketorolac tromethamine, can lead to onset of new hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of CV events

Archived from the original on December 22, 2017

Clinical and structural evaluations were performed with widely used methodologies including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and measurements of the size and depth of the cartilage defect, signal intensity of regenerated cartilage, and cartilage volume using magnetic resonance imaging (MRI)

It is the only peptide in this guide that is FDA-approved with a primary indication for reducing abdominal fat, placing it in a unique regulatory position among the best peptides for weight loss targeting visceral adiposity

Journal of the American Geriatrics Society 1998;46:11257